Opens in a new tab or window or on the link below. Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men. Although ...

A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, Ph.D., has discovered a new ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Opens in a new tab or window The phase III ARANOTE trial showed that darolutamide and androgen-deprivation therapy (ADT) without chemotherapy could be an effective option for some patients with ...

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a ...

PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for metastatic castration-sensitive prostate cancer (mCSPC).

This page includes links to articles highlighting the top genitourinary cancer research published on Cancer Therapy Advisor in 2024.